Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy

Paediatrics and Child Health

Volumn 16, Issue 8, 2011, Pages 479-484

  Miura, Masaru ^a   Tamame, Takuya ^a   Naganuma, Takashi ^a   Chinen, Shino ^a   Matsuoka, Megumi ^a   Ohki, Hirotaka ^a  

^a TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Coronary artery lesions; Kawasaki disease; Nonresponders to intravenous immunoglobulin; Prednisolone; Steroid pulse

Indexed keywords

ACETYLSALICYLIC ACID; FAMOTIDINE; HEPARIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CORONARY ARTERY DISEASE; CORONARY ARTERY LESION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; INFANT; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PROSPECTIVE STUDY; SINUS BRADYCARDIA; STEROID THERAPY; TREATMENT RESPONSE;

EID: 80053926740     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.8.479     Document Type: Article

References (29)

1. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2001;154:694-9.
2. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:e78.
3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. (Pubitemid 41754943)
4. Saji T, Sonobe T, Uemura S, Akagi T, Ayusawa M. [Guideline for treatment of acute Kawasaki disease.] J Jap Pediatr Soc 2003;107:1713-5. (Japanese).
5. Brogan P, Bose A, Burgner D, et al. Kawasaki disease: An evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86:286-90. (Pubitemid 34289632)
6. Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 2004;89:776-80.
7. Son MBF, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: Analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009;124:1-8.
8. Kato H, Koike S, Yokoyama T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9. (Pubitemid 9083134)
9. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90;1096-7. (Pubitemid 41406624)
10. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7. (Pubitemid 32640933)
11. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75.
12. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare, 1984.
13. Davignon A, Rautaharju P, Boisselle E, Soumis F, Mégélas M, Choquette A. Normal ECG standards for infants and children. Pediatr Cardiol 1979/80;1:123-52.
14. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(Suppl):555-76.
15. Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: Results from the nationwide survey in 2005. J Epidemiol 2008;18:167-72.
16. The Nationwide Survey Group of Kawasaki Disease. [Report of the 20th Nationwide Survey of Kawasaki Disease.] Tokyo: Japan Kawasaki Disease Research Center, 2009 (Japanese).
17. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
18. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009;53:15-9.
19. Naoe S, Takahashi K, Masuda H, et al. Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn 1991;41:785-97.
20. Kato H. Cardiovascular involvement in Kawasaki disease: Evaluation and natural story. In: Shulman ST, ed. Kawasaki Disease. New York: Alan R Liss, 1987:277-86.
21. Pentikäinen PJ. Pharmacological aspects of corticosteroid pulse therapy. Scand J Rheumatol 1984;54(Suppl):6-9. (Pubitemid 14048861)
22. Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006;148:800-5. (Pubitemid 43870089)
23. Makata H, Ichiyama T, Uchi R, Takekawa T, Matsubara T, Furukawa S. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: Implication for treatment of Kawasaki disease. Naunyn Schmiedebergs Arch Pharmacol 2006;373:325-32. (Pubitemid 44215578)
24. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3. (Pubitemid 32881104)
25. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:525-33.
26. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7. (Pubitemid 37188322)
27. Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008;167:1119-23.
28. Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004;19:1232-6. (Pubitemid 39462423)
29. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93. (Pubitemid 28027615)